close

How a drug company made $114 billion by gaming the US patent system

The incident has become a case study in how drug companies artificially prop up prices of their best-selling drugs

NYT
Pharma Sector, Pharma Companies
Premium

In 2016, a blockbuster drug called Humira was poised to become a lot less valuable.
The key patent on the best-selling anti-inflammatory medication, used to treat conditions like arthritis, was expiring at the end of the year. Regulators had blessed a rival version of the drug, and more copycats were close behind. The onset of competition seemed likely to push down the medication’s $50,000-a-year list price.
Instead, the opposite happened.
Or

Also Read

FDA acknowledges delays in response to US Infant formula shortage

Govt, pharma companies working on pricing mechanism for off-patent drugs

Algo rhythm: India's global patent share now higher than UK, shows data

Floods trap many in Florida as Hurricane Ian heads to South Carolina

Indian student leads 'plogging' missions to clean up streets across UK

US investigates self-driving claims made by Elon Musk for Tesla: Report

UK regional airline Flybe slumps into bankruptcy for second time in 3 years

Twitter will take 'less severe action' against accounts that break rules

Tesla CEO Elon Musk meets US officials to discuss electric vehicles

European Union mulls $100 a barrel price cap for Russia diesel exports

First Published: Jan 29 2023 | 10:39 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers. Already a BS Premium subscriber?LOGIN NOW

Register to read more on Business-Standard.com